Literature DB >> 15140979

Reduced sensitivity to human serum inactivation of enveloped viruses produced by pig cells transgenic for human CD55 or deficient for the galactosyl-alpha(1-3) galactosyl epitope.

Saema Magre1, Yasuhiro Takeuchi, Gillian Langford, Andrew Richards, Clive Patience, Robin Weiss.   

Abstract

Complement activation mediated by the major xenogeneic epitope in the pig, galactosyl-alpha(1-3) galactosyl sugar structure (alpha-Gal), and human natural antibodies could cause hyperacute rejection (HAR) in pig-to-human xenotransplantation. The same reaction on viruses bearing alpha-Gal may serve as a barrier to zoonotic infection. Expressing human complement regulatory proteins or knocking out alpha-Gal epitopes in pig in order to overcome HAR may therefore pose an increased risk in xenotransplantation with regard to zoonosis. We investigated whether amphotropic murine leukemia virus, porcine endogenous retrovirus, and vesicular stomatitis virus (VSV) budding from primary transgenic pig aortic endothelial (TgPAE) cells expressing human CD55 (hCD55 or hDAF) was protected from human-complement-mediated inactivation. VSV propagated through the ST-IOWA pig cell line, in which alpha-galactosyl-transferase genes were disrupted (Gal null), was also tested for sensitivity to human complement. The TgPAE cells were positive for hCD55, and all pig cells except the Gal-null ST-IOWA expressed alpha-Gal epitopes. Through antibody binding, we were able to demonstrate the incorporation of hCD55 onto VSV particles. Viruses harvested from TgPAE cells were relatively resistant to complement-mediated inactivation by the three sources of human sera tested. Additionally, VSV from Gal-null pig cells was resistant to human complement inactivation. Such protection of enveloped viruses may increase the risk of zoonosis from pigs genetically modified for pig-to-human xenotransplantation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140979      PMCID: PMC415822          DOI: 10.1128/JVI.78.11.5812-5819.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Cloned pigs produced by nuclear transfer from adult somatic cells.

Authors:  I A Polejaeva; S H Chen; T D Vaught; R L Page; J Mullins; S Ball; Y Dai; J Boone; S Walker; D L Ayares; A Colman; K H Campbell
Journal:  Nature       Date:  2000-09-07       Impact factor: 49.962

2.  Human CD59 incorporation into porcine endogenous retrovirus particles: implications for the use of transgenic pigs for xenotransplantation.

Authors:  Daniel M Takefman; Gregory T Spear; Mohammed Saifuddin; Carolyn A Wilson
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  Identification of novel porcine endogenous betaretrovirus sequences in miniature swine.

Authors:  T Ericsson; B Oldmixon; J Blomberg; M Rosa; C Patience; G Andersson
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning.

Authors:  Liangxue Lai; Donna Kolber-Simonds; Kwang-Wook Park; Hee-Tae Cheong; Julia L Greenstein; Gi-Sun Im; Melissa Samuel; Aaron Bonk; August Rieke; Billy N Day; Clifton N Murphy; David B Carter; Robert J Hawley; Randall S Prather
Journal:  Science       Date:  2002-01-03       Impact factor: 47.728

5.  Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV).

Authors:  G T Spear; N S Lurain; C J Parker; M Ghassemi; G H Payne; M Saifuddin
Journal:  J Immunol       Date:  1995-11-01       Impact factor: 5.422

6.  Characterization of human IgG-binding xenoantigens expressed by porcine aortic endothelial cells.

Authors:  S P Cooke; R A Hederer; J D Pearson; C O Savage
Journal:  Transplantation       Date:  1995-12-15       Impact factor: 4.939

7.  Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury.

Authors:  K R McCurry; D L Kooyman; C G Alvarado; A H Cotterell; M J Martin; J S Logan; J L Platt
Journal:  Nat Med       Date:  1995-05       Impact factor: 53.440

8.  Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase.

Authors:  Y Takeuchi; C D Porter; K M Strahan; A F Preece; K Gustafsson; F L Cosset; R A Weiss; M K Collins
Journal:  Nature       Date:  1996-01-04       Impact factor: 49.962

9.  Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.

Authors:  M Saifuddin; C J Parker; M E Peeples; M K Gorny; S Zolla-Pazner; M Ghassemi; I A Rooney; J P Atkinson; G T Spear
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

10.  A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody.

Authors:  R P Rother; W L Fodor; J P Springhorn; C W Birks; E Setter; M S Sandrin; S P Squinto; S A Rollins
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  7 in total

1.  Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion.

Authors:  Moanaro Biswas; John B Johnson; Sandeep R P Kumar; Griffith D Parks; Subbiah Elankumarana; Elankumaran Subbiah
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

2.  Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.

Authors:  Marlén M I Aasa-Chapman; Sophie Holuigue; Keith Aubin; Mailee Wong; Nicola A Jones; David Cornforth; Pierre Pellegrino; Philippa Newton; Ian Williams; Persephone Borrow; Aine McKnight
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3.  Vibrio vulnificus biotype 2 serovar E gne but not galE is essential for lipopolysaccharide biosynthesis and virulence.

Authors:  Esmeralda Valiente; Natalia Jiménez; Susana Merino; Juan M Tomás; Carmen Amaro
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

4.  A comprehensive microbiological safety approach for agarose encapsulated porcine islets intended for clinical trials.

Authors:  Lawrence S Gazda; James Collins; Archie Lovatt; Robert W Holdcraft; Merribeth J Morin; Daniel Galbraith; Melanie Graham; Melissa A Laramore; Christine Maclean; John Black; Euan W Milne; Douglas G Marthaler; Horatiu V Vinerean; Michelle M Michalak; Deborah Hoffer; Steven Richter; Richard D Hall; Barry H Smith
Journal:  Xenotransplantation       Date:  2016-11-11       Impact factor: 3.907

5.  Functional Dissection of the Dominant Role of CD55 in Protecting Vesicular Stomatitis Virus against Complement-Mediated Neutralization.

Authors:  Nisha Asok Kumar; Sreenath Muraleedharan Suma; Umerali Kunnakkadan; Joydeep Nag; Reshma Koolaparambil Mukesh; Douglas S Lyles; John Bernet Johnson
Journal:  Viruses       Date:  2021-02-26       Impact factor: 5.048

6.  Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors.

Authors:  B-Y Hwang; D V Schaffer
Journal:  Gene Ther       Date:  2013-01-31       Impact factor: 5.250

7.  Social and environmental risk factors in the emergence of infectious diseases.

Authors:  Robin A Weiss; Anthony J McMichael
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.